View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
July 11, 2011updated 17 Aug 2022 12:17pm

Synta Reports Positive Results from Ganetespib Trial

Synta Pharmaceuticals has reported positive results from a Phase II single-agent clinical trial of ganetespib in patients with advanced non-small cell lung cancer who had failed prior therapy. Ganetespib is a potent, synthetic, small-molecule inhibitor of heat-shock protein 90, a molecu

By cms admin

Synta Pharmaceuticals has reported positive results from a Phase II single-agent clinical trial of ganetespib in patients with advanced non-small cell lung cancer who had failed prior therapy.

Ganetespib is a potent, synthetic, small-molecule inhibitor of heat-shock protein 90, a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins.

In the trial ganetespib showed tumour shrinkage in target lesions, improved disease control rate and objective response rate.

Julie Brahmer of the Johns Hopkins Hospital’s Sidney Kimmel Comprehensive Cancer Center said the results suggest that ganetespib has promising potential to benefit lung cancer patients, particularly with ALK or KRAS mutations.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology